PORT WASHINGTON, N.Y.,
July 1, 2021 /PRNewswire/
-- Pall Corporation, a global leader in filtration, separation
and purification, today announced a new contract worth more than
$7M with full-service contract
development and manufacturing organization (CDMO) Exothera
S.A.
The new contract with Pall will establish a suspension-based
manufacturing platform of up to 2000L, using a range of
technologies including Allegro™ STR single-use
bioreactors. The new installation allows for the production of
a variety of viral vectors for gene therapies and viral
vector-based vaccines.
Exothera recently announced a significant expansion of its
manufacturing capabilities, with two new state-of-the-art Good
Manufacturing Practice (GMP) facilities built at the company's
Jumet site near Brussels, Belgium.
The new facilities, which are roughly 92,000 square feet and
include a variety of functions from research and development to
commercial production, will begin GMP production this summer.
Clive Glover, General Manager,
Gene Therapy at Pall Corporation,
said: "There is a strong pipeline of viral vector-based gene
therapies and vaccines and the importance of rapidly realizing
industrial-scale production for these vaccines and therapies has
been brought into sharp focus by COVID-19. Pall has
considerable process development expertise from working with many
of the industry leaders to develop scalable upstream and downstream
processes. We're thrilled to bring this experience to support
Exothera as they expand their manufacturing capabilities."
The gene therapy and vaccine industries are facing complex
challenges when scaling up vector-based processes. According to
Vasily Medvedev, head of development
at Exothera, the company selected the Pall end-to-end solution
based on its flexibility and its capability to scale up processes
quickly and efficiently.
"We selected Pall for their technological excellence and strong
track record in the gene therapy and vaccines industries, as well
as the level of support the team provides," explained
Medvedev. "They offer a robust and cost-effective single-use
solution."
Christian Borgniet, Chief Operating Officer of Exothera, added:
"Compared to other suspension solutions, Pall's STR bioreactors are
well-suited and could be adapted, if needed, to the perfusion mode,
allowing higher growth and density of cells. We are pleased to
establish this partnership with a very supportive company that is
willing to transfer its expertise."
About Pall Corporation
Pall Corporation is a
filtration, separation and purification leader providing solutions
to meet the critical fluid management needs of customers across the
broad spectrum of life sciences and industry. Pall works with
customers to advance health, safety and environmentally responsible
technologies. The Company's engineered products enable process and
product innovation and minimize emissions and waste. Pall
Corporation serves customers worldwide. For more information visit
https://www.pall.com.
Or follow us on social media:
LinkedIn
Twitter Facebook
Corporate Media Contact:
Pall Corporation
Amanda Comeau
Director, Corporate Communications
(508) 330-0811
About Exothera SA
Exothera is a viral vector CDMO
(contract manufacturing and development organization) leveraging
standard and innovative bioproduction platforms to rapidly deliver
affordable viral vector-based vaccines and cell and gene therapies.
As a Univercells company, Exothera capitalizes on novel
manufacturing technologies and best-in-class bioprocessing
expertise to provide bespoke process optimization and GMP clinical
and commercial production of viral vectors. Based on its extensive
technology expertise, Exothera selects technologies to optimally
answer customer needs for cost-effective and agile viral vector
manufacturing.
LinkedIn: https://www.linkedin.com/company/exothera /
Website: www.exothera.world
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pall-corporation-secures-multi-million-dollar-contract-with-exothera-301323764.html
SOURCE Pall Corporation
